{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:51:41Z","timestamp":1780527101363,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Pfizer Australia Pty Ltd"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.ejca.2011.04.024","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T02:16:54Z","timestamp":1308622614000},"page":"1826-1836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Stephen J.","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy A.","family":"van Hazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Ransom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Mark","family":"Jeffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall C.","family":"Tebbutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond M.","family":"Lowenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. John","family":"Simes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2011.04.024_b0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ctrv.2009.04.003","article-title":"Chemotherapy for operable and advanced colorectal cancer","volume":"35","author":"Aschele","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.ejca.2011.04.024_b0010","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2011.04.024_b0015","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2011.04.024_b0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000229787","article-title":"Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer","volume":"77","author":"Sobrero","year":"2009","journal-title":"Oncology"},{"issue":"17","key":"10.1016\/j.ejca.2011.04.024_b0025","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2011.04.024_b0030","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0305-7372(10)00036-8","article-title":"The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer","volume":"36","author":"Bouche","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ejca.2011.04.024_b0035","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial","volume":"21","author":"Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9138","key":"10.1016\/j.ejca.2011.04.024_b0040","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"issue":"9138","key":"10.1016\/j.ejca.2011.04.024_b0045","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2011.04.024_b0050","unstructured":"Frontini L, Labianca R, Sobrero A, et al. Irinotecan (CPT-11) is effective as second-line chemotherapy in advanced colorectal cancer (ACC): a phase II trial of GISCAD (Italian Group for the Study of Gastrointestinal Cancer) (Meeting abstract). Annual Meeting of the American Society of Clinical Oncology; 1999:Abstract 1000."},{"issue":"Suppl 8","key":"10.1016\/j.ejca.2011.04.024_b0055","article-title":"Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from the clinical practice","volume":"20","author":"Bittoni","year":"2009","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2011.04.024_b0060","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2011.04.024_b0065","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ejca.2011.04.024_b0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(07)70148-1","article-title":"Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial","volume":"8","author":"Stockler","year":"2007","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2011.04.024_b0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2011.04.024_b0080","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.1996.14.4.1128","article-title":"Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer","volume":"14","author":"Rothenberg","year":"1996","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2011.04.024_b0085","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1200\/JCO.1997.15.8.2910","article-title":"Phase II trial of irinotecan in patients with metastatic colorectal carcinoma","volume":"15","author":"Pitot","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2011.04.024_b0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","article-title":"Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy","volume":"15","author":"Rougier","year":"1997","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.ejca.2011.04.024_b0095","first-page":"45","article-title":"Phase II Study of Irinotecan (CPT-11) in patients with 5-Fluorouracil-refractory metastatic colorectal carcinoma \u2013 An Asian experience","volume":"9","author":"Ang","year":"1998","journal-title":"Ann Oncol"},{"issue":"Supp4","key":"10.1016\/j.ejca.2011.04.024_b0100","first-page":"18","article-title":"The experience of the TTD Spanish Cooperative Group in advanced colorectal cancer resistant to 5-FU with irinotecan (CPT-11) on a 3 weeks schedule: Final results. 23rd Congress of the European Society for Medical Oncology (ESMO)","volume":"9","author":"Ant\u00f3n","year":"1998","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.ejca.2011.04.024_b0105","first-page":"45","article-title":"Irinotecan (CPT-11) in pretreated metastatic colorectal cancer (CRC)","volume":"9","author":"Lara","year":"1998","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2011.04.024_b0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1040-8428(99)00045-1","article-title":"Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy","volume":"32","author":"Aravantinos","year":"1999","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2011.04.024_b0115","unstructured":"Hoeffken K, Ridwelsky C, Wein A, et al. Phase II Study of Irinotecan as Second Line Chemotherapy (CT) in Metastatic Colorectal Cancer (CRC). (Meeting abstract). ASCO Annual Meeting 1999:Abstract No: 937."},{"issue":"4","key":"10.1016\/j.ejca.2011.04.024_b0120","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9","article-title":"A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma","volume":"85","author":"Rothenberg","year":"1999","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2011.04.024_b0125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0959-8049(98)00353-0","article-title":"Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)","volume":"35","author":"Van Cutsem","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2011.04.024_b0130","article-title":"Phase II study of irinotecan as second line chemotherapy in metastatic colorectal cancer after prior exposure to infusional 5-FU-based chemotherapy","volume":"19","author":"Sch\u00f6ffski","year":"2000","journal-title":"Proc ASCO Annual Meeting"},{"issue":"1","key":"10.1016\/j.ejca.2011.04.024_b0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00000421-200102000-00021","article-title":"Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer","volume":"24","author":"Gil-Delgado","year":"2001","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2011.04.024_b0140","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.bjc.6600641","article-title":"Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer","volume":"87","author":"Leonard","year":"2002","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2011.04.024_b0145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000057669","article-title":"Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination","volume":"48","author":"Tsavaris","year":"2002","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1016\/j.ejca.2011.04.024_b0150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","article-title":"Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer","volume":"21","author":"Fuchs","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2011.04.024_b0155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3816\/CCC.2003.n.023","article-title":"A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil","volume":"3","author":"Mendez","year":"2003","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2011.04.024_b0160","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00280-003-0659-z","article-title":"Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study","volume":"52","author":"Tsavaris","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.ejca.2011.04.024_b0165","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2004.01.005","article-title":"A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer","volume":"22","author":"Lal","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2011.04.024_b0170","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2011.04.024_b0175","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/BF02710170","article-title":"Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy","volume":"7","author":"Garcia-Giron","year":"2005","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2011.04.024_b0180","first-page":"169","article-title":"A randomised phase II study of irinotecan in combination with 5-FU\/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma","volume":"30","author":"Graeven","year":"2007","journal-title":"Onkologie"},{"issue":"9582","key":"10.1016\/j.ejca.2011.04.024_b0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","article-title":"Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial","volume":"370","author":"Koopman","year":"2007","journal-title":"Lancet"},{"issue":"9582","key":"10.1016\/j.ejca.2011.04.024_b0190","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejca.2011.04.024_b0195","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000102583","article-title":"Sequential administration of 5-fluorouracil (5FU)\/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU\/LV in advanced colorectal carcinoma. A phase III randomized study","volume":"53","author":"Tsavaris","year":"2007","journal-title":"Chemotherapy"},{"issue":"28","key":"10.1016\/j.ejca.2011.04.024_b0200","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1200\/JCO.2008.17.1249","article-title":"Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma","volume":"26","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2011.04.024_b0205","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2008.20.4552","article-title":"Phase III non-inferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2011.04.024_b0210","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1592\/phco.28.6.742","article-title":"Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer","volume":"28","author":"Jean","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.ejca.2011.04.024_b0215","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejon.2010.03.004","article-title":"C. B-D. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer","volume":"14","author":"Ouwerkerk","year":"2010","journal-title":"Eur J Oncol Nurs"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911003030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911003030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T01:42:48Z","timestamp":1682473368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911003030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0959804911003030"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.04.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2011.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}